Beruflich Dokumente
Kultur Dokumente
MD
Epidemiology
Worldwide prevalence of 7-11%
Lovell RM, Ford AC. Global Prevealence of and Risk Factors for Irritable Bowel Syndrome:
a Meta-analysis. Clinical Gastroenterology and Hepatology 2012:10(7); 712-21.
Epidemiology and Disease Burden
Prevalence in North America about 7-15%
F:M ratio 1.5-3:1
Over $20 billion in annual direct and indirect costs
Estimated 3.6 million physician visits for IBS in the
U.S. annually
Associated with decreased quality of life
Andrews EB , Eaton SC , Hollis KA et al. Prevalence and demographics of irritable bowel
syndrome: results from a large web-based survey. Aliment Pharmacol Ther 2005;22: 935–42.
Survey of >31,000 patients
7 % prevalence for IBS
prevalence increased as income decreased
9.0% (CI: 8.1–10.0) among individuals with an annual
income <$20,000 vs. 5.2% (CI: 4.7–5.8) in the highest
income group
Unemployed individuals had a higher prevalence of IBS
(10.0%, CI: 8.9–11.1) than those who were employed
(5.9%; CI: 5.6–6.3)
Andrews EB , Eaton SC , Hollis KA et al. Prevalence and demographics of irritable bowel syndrome:
results from a large web-based survey. Aliment Pharmacol Ther 2005;22: 935–42 .
Diagnosis
Manning criteria 1978
Rome I 1990
Rome II 1999
Rome III 2006
Rome IV ????
Manning Criteria 1978
Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel
syndrome. Its value in the exclusion of organic disease. Gastroenterology 1984;87:1–7.
Rome III
Recurrent abdominal pain or discomfort at least 3 days
per month in past 3 months and at least 2 other
features:
Improvement with defecation
Onset associated with change in stool frequency
Onset associated with change in stool form
(appearance)
IBS Classifications
Feldman M, Friedman FS, et al. Irritable Bowel Syndrome. Gastroenterology and Liver
Disease Ninth Edition 2010(118)2091-2104.
Other complaints
Abdominal bloating Dysmenorrhea
Increased flatulence Impaired sexual function
Nausea Dyspareunia
Reflux Urinary
Dysphagia frequency/urgency
Non-cardiac chest pain Fibromyalgia symptoms
Other considerations
Celiac disease
Lactose intolerance
SIBO
IBD
Neoplasia
Microscopic colitis
Infections
Chronic pancreatitis
Alarm features
Weight loss
Iron deficiency anemia
Rectal bleeding
Nocturnal symptoms
Family history of selected organic diseases including
colorectal cancer, IBD and celiac disease
ACG Recommendations (2009)
“Routine diagnostic testing with complete blood count,
serum chemistries, thyroid function studies, stool for
ova and parasites, and abdominal imaging is not
recommended in patients with typical IBS symptoms
and no alarm features because of a low likelihood of
uncovering organic disease.”
“Routine serologic screening for celiac sprue should be
pursued in patients with IBS-D and IBS-M”
Constipation:
AXR
Consider colonoscopy/sigmoidoscopy
In 2006, NIH disbursed $18,787,710 for IBS-related
research
Pathophysiology
Psychosocial dysfunction
Motility
Hypersensitivity
Bacterial overgrowth
Microflora alteration
Intestinal Inflammation
Postinfectious
Food Sensitivity
Genetics
Afferent pathways
Dorn SD, Palsson OS. Increased colonic pain sensitivity in irritable bowel syndrome is the result of an
increased tendency to report pain rather than increased neurosensory sensitivity. Gut 2007;56:1202–09.
Brain Imaging and
Visceral Hypersensitivity
Meta-analysis of 16 fMRI or PET studies from 1997-
2010
Brain activation in IBS vs controls during rectal ballon
distention
Inconclusive findings with no significant difference in
any region of the brain
Further studies with standardization of protocol
recommended
Sheehan J, Gaman A, et al. Pooled analysis of brain activity in irritable bowel syndrome and
controls during rectal balloon distension. Neurogastroenterol Motil (2011) 23:336–e158.
Abnormal Motility
Present in some patients
Increased frequency/irregularity of intestinal
contractions
(Simren M, et al Dig Dis Sci 2000; Schmidt T, et al Scand J Gastroenterol
1996)
Prolonged transit-time in IBS-C
(Agrawal, A, Houghton LA, et al. Am J Gastro 2009)
Diarrhea may be due to enhanced gastrocolic response, rectal
hypersensitivity, or increased high-amplitude propagated contractions
12 IBS patients
(minimum 4 BM’s
daily with negative
colon biopsies); 10
controls
Exaggerated response
with increased high
amplitude
propogating
contractions to meal
ingestion and to
cholecystokinin
octapeptide in IBS-D.
1.5-fold reduction
of Bifidobacteria
(P .05)
May produce
active serine
proteinase
inhibitors
5% increased
level of Firmicutes
(P .0001)
Rajilic´-Stojanovic M, Biagi E et al. Global and Deep
Molecular Analysis of Microbiota Signatures in Fecal
Samples From Patients With Irritable Bowel Syndrome.
Gastroenterology 2011;141:1792–1801.
Diet
Food Sensitivity--carbohydrate malabsorption
FODMAPs (fermentable oligo-, di-, and
monosaccharides and polyols)
Fermentation in distal small bowel/colon may cause
intestinal permeability and inflammation
Gluten sensitivity
Up to 70% of IBS patients who were HLA DQ2 positive
with negative work up for celiac disease reported
decreased symptoms after a gluten free diet compared
to 20% of HLA DQ2 negative patients
Double blind placebo trial
19 IBS patients on gluten-
P=0.02
free diet despite exclusion
of celiac disease
15 controls
2 slices of bread and a
muffin daily
P=0.001
P=0.03 No difference in HLA-DQ2
or DQ8, fecal lactoferrin,
CRP, intestinal
permeability or celiac
antibodies
Biesiekierski JR, Newnham ED. Gluten Causes
Gastrointestinal Symptoms in Subjects
Without Celiac Disease: A Double-Blind
Randomized Placebo-Controlled Trial. Am J
Gastro 2011;106:508-14.
Food Patch Testing in IBS
Stierstorfer MB, Sha CT et al. Food patch testing for irritable bowel syndrome. J Am Acad Dermatology 2012:1-8.
Psychosocial Associated Risk
Prospective study of 2456 patients without IBS
Over 15 months 3.5% developed IBS
Independent predictors of IBS onset
Anxiety (OR = 2.0; 95% CI 0.98–4.1)
Sleep problems (OR = 1.6; 95% CI 0.8–3.2)
Somatic symptoms (OR = 1.6; 95% CI 0.8–2.9)
Other studies report association with abuse, anxiety,
depression, and phobias.
Nicholl BI, Halder SL. Psychosocial risk markers for new onset irritable bowel syndrome
– Results of a large prospective population-based study. Pain 2008;137:147–155.
Global Improvement Score
(1-7)
1= much worse
4 =no change
7= much better
Adequate Relief
(over past week: yes/no)
Quality of Life
(34 items, 0-100)
Kaptchuk T, Friedlander E, et al. Placebos without Deception: A Randomized
Controlled Trial in Irritable Bowel Syndrome. Plosone 2010:5(12).
Non-pharmacologic Therapies
Fiber may be beneficial in IBS-C
Lactose free, low flatulogenic, gluten-free or
FODMAPs diet
Exercise, stress management (biofeedback, hypnosis,
psychotherapy)
Therapeutic physician-patient relationship
Psychosocial Aspect
Treating bowel-related symptoms is important, but
may not be sufficient, to impact overall HRQOL.
Attempt to positively modify the cognitive
interpretation of IBS symptoms (ie, acknowledge and
address the emotional context in which symptoms
occur)
Addressing symptom-related fears/concerns;
reassurance of benign nature of diagnosis
Identifying and eliminating factors contributing to
vital exhaustion
Gauge global symptom severity
BEST Questionnaire
“How Bad are your bowel symptoms?”
“Can you still Enjoy the things you used to enjoy?”
“Do you feel like your bowel symptoms mean there’s
something Seriously wrong?”
“Do your bowel symptoms make you feel Tense?”
Scored 0-100
Correlates well with the 34 question IBS-QOL
questionnaire
Ford AC, Talley NJ, et al. Efficacy of antidepressants and psychological therapies in
irritable bowel syndrome: systematic review and meta-analysis. Gut 2009;58:367–78
Probiotics
Bifidobacterium infantis
Bifidobacterium animalis
Lactobacillus rhamnosus
Lactobacillus plantarum
Lactobacillus reuteri
Bacillus coagulans
Combinations
e.g. VSL#3: Streptococcus thermophilus, B breve, B longum, B
infantis, L acidophilus, L plantarum, L paracasei, L
delbreuckii/bulgaricus
Heterogenous studies, many with end points that are not
clinically applicable or compared with placebo.
Bifidobacterium infantis 35624 (Align)
• 362 Women with IBS
• Taken daily for 4
weeks
• Global Assessment
• “Please consider how you
felt in the past week in
regard to your IBS, in
particular your general
well-being, and
symptoms of abdominal
discomfort or pain,
bloating or distension
and altered bowel habit.
Compared to the way
you felt before beginning
the medication, have you
had adequate relief of
your IBS symptoms?”
Whorwell PJ, Altringer L, et al. Efficacy of an Encapsulated Probiotic Bifidobacterium
infantis 35624 in Women with Irritable Bowel Syndrome. Am J Gastroenterol 2006;101:1581–1590.
5-Hydroxytryptamine 3 Receptor
Antangonists
May decreased pain via modulation of visceral afferent
activity
Alosetron, Ondansetron, Granisetron, Cilansetron (FDA
application withdrawn)
Alosetron (Lotronex) developed for IBS
Reduces colonic motility and secretions
Meta-analysis showed improvement in global symptoms
and abdominal pain, mostly in females with IBS-D
Alosetron associated with:
Severe constipation
Idiosyncratic ischemic colitis (2/1000 by 3 months, 3/1000 by
6 months)
Prescription restricted
Lubiprostone (Amitiza)
Bicyclic fatty acid derived from prostaglandin E1
Increases chloride transport
ClC-2 chloride channel
CFTR chloride channels via prostanoid receptor EP4?
Approved for women with IBS-C at 8mcg BID (24 mcg
BID for chronic idiopathic constipation)
Pregnancy test recommended in women capable of
becoming pregnant as safety has not been evaluated
Lubiprostone (Amitiza)
1154 patients with IBS-C (92% female)
“How would you rate your relief of IBS symptoms (abdominal discomfort/pain,
bowel habits, and other IBS symptoms) over the past week compared to how you
felt before you entered the study?”
Responder if moderately or significantly better (6 or 7 on 7-point balanced scale)